Choose New Jersey, in collaboration with BioNJ, the HealthCare Institute of New Jersey (HINJ), JLL, and the New Jersey Economic Development Authority (NJEDA), has released the 2026 New Jersey Life Sciences Report. The in-depth analysis underscores the state’s continued evolution as a premier global hub for biotech, pharmaceutical manufacturing, and medical innovation.
The report highlights a robust ecosystem bolstered by more than $190 million in recent state investments aimed at expanding incubators and accelerator programs. These initiatives are designed to support early-stage companies and streamline the transition from research to commercialization.
“New Jersey offers one of the most advantageous environments in the world for life sciences companies,” Gov. Mikie Sherrill said. “Our state already has much to offer life sciences companies looking to grow and invest in a region with unmatched potential, and my administration is committed to making New Jersey even more business-friendly.”
The 2026 report points to several critical areas where New Jersey continues to lead:
- Manufacturing Expansion: Since 2021, the state has added 1.5 million square feet of new CDMO (Contract Development and Manufacturing Organization) and biomanufacturing space.
- Cell and Gene Therapy Leadership: New Jersey is home to six of the 13 FDA-approved cell and gene therapies in the United States.
- Infrastructure Efficiency: New R&D campuses and lab-ready facilities allow companies to reduce market entry timelines by 12 to 24 months and save up to 90% in construction costs compared to traditional development.
To support this physical growth, the state is investing heavily in human capital. Programs such as NJBioFutures are bridging the gap between industry and academia, ensuring a steady stream of job-ready talent prepared for the complexities of advanced manufacturing and biopharma research.
“The depth of New Jersey’s life sciences ecosystem presents a compelling case to investors and companies around the world,” Choose New Jersey CEO Amy Herbold said.
The report’s release coincides with the start of the 2026 BIO International Convention in San Diego, California. Choose New Jersey is utilizing the premier global event to present the state’s capabilities to more than 20,000 industry leaders, investors, and potential partners from over 90 international markets.
“New Jersey has long been at the forefront of life sciences innovation,” Debbie Hart, president and CEO of BioNJ said. “This report showcases the strength of our ecosystem and the many advantages that continue to attract companies, talent, and investment to New Jersey.”
To download the full 2026 New Jersey Life Sciences Report, visit choosenj.com.
